ZOETIS INC (ZOE.DE) Stock Price & Overview
FRA:ZOE • US98978V1035
Current stock price
The current stock price of ZOE.DE is 99.08 EUR. Today ZOE.DE is down by -0.48%. In the past month the price decreased by -1.51%. In the past year, price decreased by -25.53%.
ZOE.DE Key Statistics
- Market Cap
- 41.665B
- P/E
- 18.08
- Fwd P/E
- 16.41
- EPS (TTM)
- 5.48
- Dividend Yield
- 1.64%
ZOE.DE Stock Performance
ZOE.DE Stock Chart
ZOE.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ZOE.DE. When comparing the yearly performance of all stocks, ZOE.DE is a bad performer in the overall market: 89.14% of all stocks are doing better.
ZOE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ZOE.DE. ZOE.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
ZOE.DE Earnings
On February 12, 2026 ZOE.DE reported an EPS of 1.48 and a revenue of 2.39B. The company beat EPS expectations (4.53% surprise) and beat revenue expectations (0.13% surprise).
ZOE.DE Forecast & Estimates
25 analysts have analysed ZOE.DE and the average price target is 127.45 EUR. This implies a price increase of 28.64% is expected in the next year compared to the current price of 99.08.
For the next year, analysts expect an EPS growth of 10.17% and a revenue growth 4.85% for ZOE.DE
ZOE.DE Groups
Sector & Classification
ZOE.DE Financial Highlights
Over the last trailing twelve months ZOE.DE reported a non-GAAP Earnings per Share(EPS) of 5.48. The EPS increased by 8.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.23% | ||
| ROA | 17.28% | ||
| ROE | 80.25% | ||
| Debt/Equity | 2.71 |
ZOE.DE Ownership
ZOE.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 8.82 | 97.096B | ||
| SNW | SANOFI | 8.82 | 97.084B | ||
| SAN | SANOFI | 8.82 | 97.071B | ||
| MRK | MERCK KGAA | 14.19 | 48.652B | ||
| UNC | UCB SA | 22.97 | 47.169B | ||
| UCB | UCB SA | 22.63 | 46.488B | ||
| 1BAYN | BAYER AG-REG | 9.09 | 39.267B | ||
| BAYN | BAYER AG-REG | 8.75 | 37.823B | ||
| IPN | IPSEN | 12.88 | 13.661B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.66 | 10.352B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.089B | ||
| VIRP | VIRBAC SA | 17.7 | 3.176B | ||
| DMP | DERMAPHARM HOLDING SE | 18.51 | 2.46B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About ZOE.DE
Company Profile
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Company Info
IPO: 2013-02-01
ZOETIS INC
10 Sylvan Way
Parsippany NEW JERSEY US
Employees: 14500
Phone: 13026587581
ZOETIS INC / ZOE.DE FAQ
What does ZOE do?
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
What is the current price of ZOE stock?
The current stock price of ZOE.DE is 99.08 EUR. The price decreased by -0.48% in the last trading session.
Does ZOETIS INC pay dividends?
ZOETIS INC (ZOE.DE) has a dividend yield of 1.64%. The yearly dividend amount is currently 1.74.
What is the ChartMill technical and fundamental rating of ZOE stock?
ZOE.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the Price/Earnings (PE) ratio of ZOETIS INC (ZOE.DE)?
The PE ratio for ZOETIS INC (ZOE.DE) is 18.08. This is based on the reported non-GAAP earnings per share of 5.48 and the current share price of 99.08 EUR.
Is ZOETIS INC (ZOE.DE) expected to grow?
The Revenue of ZOETIS INC (ZOE.DE) is expected to grow by 4.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.